相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition
Arturo Cesaro et al.
BIOFACTORS (2020)
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
Daniel A. Duprez et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2020)
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
Lorenzo Da Dalt et al.
EUROPEAN HEART JOURNAL (2019)
Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors
A. F. G. Cicero et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)
Vitamin D Status and Components of Metabolic Syndrome in Older Subjects from Northern Finland (Latitude 65°North)
Shivaprakash Jagalur Mutt et al.
NUTRIENTS (2019)
Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes
Kari Antero Makela et al.
FRONTIERS IN PHYSIOLOGY (2019)
Association of Physical Activity With Telomere Length Among Elderly Adults - The Oulu Cohort 1945
Vale Stenback et al.
FRONTIERS IN PHYSIOLOGY (2019)
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
Chiara Caselli et al.
CARDIOVASCULAR DIABETOLOGY (2019)
PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Mika Hilvo et al.
ATHEROSCLEROSIS (2018)
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
Benoit J. Arsenault et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease
Tuula Saukkonen et al.
SCIENTIFIC REPORTS (2018)
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Eeva Sliz et al.
CIRCULATION (2018)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
Luiz Sergio F. de Carvalho et al.
DIABETES CARE (2018)
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer et al.
CIRCULATION (2017)
Measuring Physical Activity in Free-Living Conditions-Comparison of Three Accelerometry-Based Methods
Anna-Maiju Leinonen et al.
FRONTIERS IN PHYSIOLOGY (2017)
PCSK9 and diabetes: is there a link?
Amir Abbas Momtazi et al.
DRUG DISCOVERY TODAY (2017)
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2016)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
Helen M. Colhoun et al.
EUROPEAN HEART JOURNAL (2016)
Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders
Daiana Ibarretxe et al.
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS (2016)
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Ymene Nekaies et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Prediabetes diagnosis and treatment: A review
Nidhi Bansal
WORLD JOURNAL OF DIABETES (2015)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins
Arjan J. Kwakernaak et al.
CLINICAL BIOCHEMISTRY (2014)
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
Yan Zhang et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
Ding Ai et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study
M. C. G. J. Brouwers et al.
ATHEROSCLEROSIS (2011)
Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes
Bruno Verges et al.
ATHEROSCLEROSIS (2011)
Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
Shelby Sullivan et al.
TRANSLATIONAL RESEARCH (2011)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism
Pasi Soininen et al.
ANALYST (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
Giorgio Bedogni et al.
BMC GASTROENTEROLOGY (2006)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
The Dallas Heart Study: A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health
RG Victor et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
分享论文
